SCHEMBL19638078

SCHEMBL19638078

COC(=O)c1ccc(C(=O)Nc2nc(-c3ccccc3)c(Cl)s2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.50
MEN1 O00255 5/20 0.50
RAB9A P51151 4/20 0.50
LMNA P02545 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
PKM P14618 1/20 0.50
ALOX5 P09917 1/20 0.49
ADORA1 P30542 5/20 0.48
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 3/20 0.47
ADORA3 P0DMS8 5/20 0.47
ADORA2A P29274 1/20 0.46
MAPT P10636 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HTT P42858 1/20 0.46
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19638183 0.90 KMT2A (0.51) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19638017 0.88 MAPT (0.52) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19637967 0.86 KMT2A (0.50) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL21168721 0.86 KMT2A (0.50) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19638022 0.86 KMT2A (0.50) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19637926 0.84 MAPT (0.52) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19638040 0.83 ADORA2A (0.60) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19638248 0.81 RAB9A (0.54) KMT2ARAB9ALMNANPSR1ADORA1
SCHEMBL19638277 0.75 SMN1; SMN2 (0.52) KMT2AMEN1RAB9ALMNANPSR1
SCHEMBL19638110 0.75 RAB9A (0.51) KMT2AMEN1RAB9ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207445-B Adenosine A3Modulators of receptors 帕罗生物制药有限公司 2021-03-16 CN disclosed
EP-3248964-B1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA SL (ES) 2019-07-17 EP disclosed
US-10238637-B2 Modulators of the adenosine A3 receptors PALOBIOFARMA, S.L. (ES) 2019-03-26 US disclosed
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS PALOBIOFARMA, S.L. (ES) 2018-09-20 US disclosed
EP-3248964-A1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA S.L. (ES) 2017-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS ADORA3, ADORA2A, ADORA1 KMT2A 4093/4885MEN1 3374/4885RAB9A 2858/4885
US-10238637-B2 Modulators of the adenosine A3 receptors ADORA3, ADORA2A, ADORA1 KMT2A 4093/4885MEN1 3374/4885RAB9A 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.